Project Grant R01GM160432
- The National Institute of General Medical Sciences awarded the University of Connecticut Health Center $423,352 on March 18, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate dead cell-phagocyte interaction at the phagosomal interface. The award funds research using a proximity-labeling technique called PhagoP1 to profile protein compositions of dead-cell-containing phagosomes and decode death-associated cellular responses. The research applies this...
- The National Institute of General Medical Sciences awarded the University of California, Berkeley $329,491 under the Biomedical Research and Research Training program (CFDA 93.859) on August 1, 2026, to elucidate the molecular basis of necroptosis through a five-year project extending to May 31, 2031. The funded research investigates the ZBP1-RIPK3-MLKL necroptosis pathway, specifically how ZBP1 transitions from inactive to assembled states to engage RIPK3, how MLKL undergoes conformational...
- The National Institute of Allergy and Infectious Diseases awarded the University of Connecticut Health Center $616,782 on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support molecular mechanisms research on Shiga toxin-mediated cell death. The funded research investigates how Shiga toxin produced by enterohemorrhagic Escherichia coli kills human cells through apoptotic, pyroptotic, or necroptotic pathways. The work aims to characterize the...
- The National Institute of General Medical Sciences awarded the University of California, San Diego $233,283 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate how tissue environment shapes neutrophil cell death fate and function. The research integrates live tissue imaging, spatial transcriptomics, chromatin profiling, and genetic models to define the fundamental rules governing whether neutrophils undergo netosis, apoptosis, or...
- The National Institute of General Medical Sciences awarded the University of Connecticut Health Center $457,875 on February 13, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate mechanisms of translational response to stress, specifically how organisms regulate errors during mRNA translation to resist and acclimate to cellular stresses. The research focuses on two families of translation factors: tryptophanyl-tRNA synthetase (TrpRS) and aminoacyl-tRNA...
- The National Institute of General Medical Sciences awarded the University of Miami $501,165 on April 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support structural and biophysical research on three human membrane proteins with significance to cardiovascular health, hemostasis, and inflammation. The funded research determines the structures and functional mechanisms of connexin channels, which coordinate electrical and metabolic activity in cardiac...
- The National Institute of General Medical Sciences awarded the University of Connecticut $446,875 on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop a soft, morphable hybrid electronic and microfluidic platform for drug screening in engineered human tissues. The research focuses on fabricating three integrated components: 3D multimodal electronic sensors (temperature, pressure, stimulation electrodes, and aptamer-based biomarker sensors) to...
- The National Institute of General Medical Sciences awarded the University of Connecticut $607,470 on March 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop mass spectrometry-based methods for sequencing large modified RNA molecules. The project, designated R01GM162759, runs through February 28, 2030, with place of performance in Storrs, Connecticut. The funded research aims to remove analytical barriers that have limited adoption of mass...
- The National Institute of General Medical Sciences awarded Massachusetts Institute of Technology $438,788 in project grant funding on July 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support research on microbial manipulation of eukaryotic membranes. The research examines how bacteria including Listeria monocytogenes and Rickettsia parkeri manipulate host cell membranes to disseminate through tissues and cross cellular compartments. The study focuses...
- The National Institute of General Medical Sciences awarded Jackson Laboratory $506,000 on March 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate the interplay between quaking (QKI) isoforms and N7-methylguanosine (M7G) RNA modifications in controlling post-transcriptional gene regulation during cellular differentiation. The project will develop novel methods for base-resolution M7G detection using direct RNA long-read sequencing and orthogonal...
The National Institute of General Medical Sciences awarded $429,072 to the University of Connecticut Health Center on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate the molecular mechanism of necroptosis mediated by the mixed lineage kinase-like (MLKL) protein. The research addresses the structure-activity relationship of MLKL, the terminal executioner of necroptosis—a pro-inflammatory form of lytic cell death implicated in cancer, diabetes, inflammatory disorders, neurodegenerative diseases, and infections. The work comprises three parallel investigation tracks. The first analyzes the recently identified MLKL-like protein NS3 in norovirus, examining the molecular mechanisms of assembly, lipid-binding, and membrane insertion during viral infection-induced necroptotic cell death using cryo-EM structures. The second directly investigates human MLKL to dissect membrane rupture mechanisms in necroptosis by determining structures of MLKL in multiple functional states, from inactive forms to active assemblies. The third extends the research to MLKL-like proteins in bacteria, building on identified bacterial MLKL-like proteins with validated in vitro membrane permeabilization activities. Place of performance is Farmington, Connecticut. The period of performance runs from September 1, 2026, through May 31, 2030. The assistance type is a Project Grant. This award funds investigator-initiated basic research designed to advance understanding of biological processes underlying disease diagnosis, treatment, and prevention.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $429.1k | 8/26/26 |